187 related articles for article (PubMed ID: 37306521)
1. Association between immune checkpoint inhibitor-induced myocarditis and concomitant use of thiazide diuretics.
Mitsuboshi S; Hamano H; Niimura T; Ozaki AF; Patel PM; Lin TJ; Tanaka Y; Kimura I; Iwata N; Shiromizu S; Chuma M; Koyama T; Yamanishi Y; Kanda Y; Ishizawa K; Zamami Y
Int J Cancer; 2023 Oct; 153(8):1472-1476. PubMed ID: 37306521
[TBL] [Abstract][Full Text] [Related]
2. Comments on "Association between immune checkpoint inhibitor-induced myocarditis and concomitant use of thiazide diuretics".
Guven DC
Int J Cancer; 2024 Feb; 154(3):585. PubMed ID: 37855166
[No Abstract] [Full Text] [Related]
3. Reply to: Comments on "Association between immune checkpoint inhibitor-induced myocarditis and concomitant use of thiazide diuretics".
Mitsuboshi S; Hamano H; Zamami Y
Int J Cancer; 2024 Feb; 154(3):586-587. PubMed ID: 37850308
[No Abstract] [Full Text] [Related]
4. Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems.
Ma R; Wang Q; Meng D; Li K; Zhang Y
BMC Cancer; 2021 Jan; 21(1):38. PubMed ID: 33413213
[TBL] [Abstract][Full Text] [Related]
5. Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database.
Chen P; Zhu J; Xu Y; Huang Q; Su J; Gao Z; Feng M
BMC Nephrol; 2023 Apr; 24(1):107. PubMed ID: 37087434
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular toxicity profiles of immune checkpoint inhibitors with or without angiogenesis inhibitors: a real-world pharmacovigilance analysis based on the FAERS database from 2014 to 2022.
Wang Y; Cui C; Deng L; Wang L; Ren X
Front Immunol; 2023; 14():1127128. PubMed ID: 37292205
[TBL] [Abstract][Full Text] [Related]
7. Disproportionality analysis of acetaminophen-induced hepatic disorders with and without immune checkpoint inhibitors.
Yamada T; Kato R; Ijiri Y; Nishihara M; Neo M
Int J Clin Pharm; 2023 Apr; 45(2):442-450. PubMed ID: 36609809
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.
Salem JE; Manouchehri A; Moey M; Lebrun-Vignes B; Bastarache L; Pariente A; Gobert A; Spano JP; Balko JM; Bonaca MP; Roden DM; Johnson DB; Moslehi JJ
Lancet Oncol; 2018 Dec; 19(12):1579-1589. PubMed ID: 30442497
[TBL] [Abstract][Full Text] [Related]
9. Association of Thiazide Diuretics With Diabetes Progression, Kidney Disease Progression, Cardiovascular Outcomes, and Death Among Patients With Diabetes Who Initiate Statins.
Afify H; Gonzalez-Morales U; Asmar A; Alvarez CA; Mansi IA
Am J Cardiol; 2023 Sep; 203():274-284. PubMed ID: 37516035
[TBL] [Abstract][Full Text] [Related]
10. Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis.
Hamada N; Maeda A; Takase-Minegishi K; Kirino Y; Sugiyama Y; Namkoong H; Horita N; Yoshimi R; Nakajima H;
Front Immunol; 2021; 12():803410. PubMed ID: 34938300
[TBL] [Abstract][Full Text] [Related]
11. Type 2 Diabetes and Thiazide Diuretics.
Scheen AJ
Curr Diab Rep; 2018 Feb; 18(2):6. PubMed ID: 29399724
[TBL] [Abstract][Full Text] [Related]
12. Association between diuretic use and the risk of vertebral fracture after stroke: a population-based retrospective cohort study.
Lin SM; Yang SH; Wang CY; Huang HK
BMC Musculoskelet Disord; 2019 Mar; 20(1):96. PubMed ID: 30832635
[TBL] [Abstract][Full Text] [Related]
13. Thiazide but not loop diuretics is associated with hypomagnesaemia in the general population.
Kieboom BCT; Zietse R; Ikram MA; Hoorn EJ; Stricker BH
Pharmacoepidemiol Drug Saf; 2018 Nov; 27(11):1166-1173. PubMed ID: 30095199
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitors and Venous Thromboembolism: An Analysis of the WHO Pharmacovigilance Database.
Allouchery M; Beuvon C; Pérault-Pochat MC; Roblot P; Puyade M; Martin M
Clin Pharmacol Ther; 2022 Jul; 112(1):164-170. PubMed ID: 35426120
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance.
Mascolo A; Scavone C; Ferrajolo C; Rafaniello C; Danesi R; Del Re M; Russo A; Coscioni E; Rossi F; Alfano R; Capuano A
Drug Saf; 2021 Sep; 44(9):957-971. PubMed ID: 34145536
[TBL] [Abstract][Full Text] [Related]
16. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
[TBL] [Abstract][Full Text] [Related]
17. Renal toxicities in immune checkpoint inhibitors with or without chemotherapy: An observational, retrospective, pharmacovigilance study leveraging US FARES database.
Hu F; Zhai Y; Yuan L; Liang J; Xu J; Guo X; Zhou X; Lin Z; Sun J; Ye X; He J
Cancer Med; 2021 Dec; 10(24):8754-8762. PubMed ID: 34845857
[TBL] [Abstract][Full Text] [Related]
18. Metabolic and Nutritional Disorders Following the Administration of Immune Checkpoint Inhibitors: A Pharmacovigilance Study.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhou X; Zheng Y; Zhao X; Xu X; Cao Y; He J
Front Endocrinol (Lausanne); 2021; 12():809063. PubMed ID: 35145482
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitor-associated myocarditis: a systematic analysis of case reports.
Wang C; Zhao G; Zhang Z; Yang L; Liu S; Li G; Wang H; Huang J; Wang S; Li N
Front Immunol; 2023; 14():1275254. PubMed ID: 37876928
[TBL] [Abstract][Full Text] [Related]
20. Type 1 diabetes with immune checkpoint inhibitors: A systematic analysis of clinical trials and a pharmacovigilance study of postmarketing data.
Zhu J; Luo M; Liang D; Gao S; Zheng Y; He Z; Zhao W; Yu X; Qiu K; Wu J
Int Immunopharmacol; 2022 Sep; 110():109053. PubMed ID: 35978507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
